Skip to main content

Tyra Biosciences, Inc. (TYRA) Stock Analysis

SellModerate Confidence

Healthcare · Biotechnology

Earnings in 7 days (2026-05-07). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $34.26: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 2.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Below-average business quality; Negative price momentum.

Tyra Biosciences is a clinical-stage precision oncology company developing oral FGFR inhibitors using its proprietary SNAP platform for targeted oncology and genetically defined conditions. Its lead program, oral dabogratinib (FGFR3-selective), is in three Phase 2 trials for... Read more

$34.26+30.2% A.UpsideScore 4.9/10#93 of 158 Biotechnology
Stop $32.30Target $44.58(analyst − 13%)A.R:R 2.6:1
Analyst target$51.24+49.6%11 analysts
$44.58our TP
$34.26price
$51.24mean
$60

Sell if holding. Engine safety override at $34.26: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 2.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.9/10, moderate confidence.

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.

Val9.0Qual1.4Grw5.0Mom2.1Sent7.8Ins3.8Peer4.4Tech7.2Risk3.24.9OVERALL

Thesis

Rewards
No bull case signals
Risks
Quality below floor (1.4 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-13.2
Mkt Cap$2.0B
EV/EBITDA-11.9
Profit Mgn0.0%
ROE-39.8%
Rev Growth—
Beta0.96
DividendNone
Rating analysts18

Quality Signals

Piotroski F2/9

Options Flow

P/C0.67bullish
IV124%elevated
Max Pain$30-12.4% vs spot

Material Events(8-K, last 90d)

  • 2026-04-17Item 5.02LOW
    Habib J. Dable appointed to the Board as Class II director, effective upon Board approval on April 16, 2026. Previously President and CEO of Acceleron Pharma; currently advisor at RA Capital Management. No arrangement with any other person.
    SEC filing →
  • 2026-04-02Item 5.02LOW
    Julia Rueb, VP Finance, designated as principal accounting officer effective April 1, 2026, succeeding CFO Alan Fuhrman in that specific role. Fuhrman continues as principal financial officer. No change in compensation terms for Rueb described.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Gross Margin
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Piotroski F
2.2
Current Ratio
5.0
Moat
5.0
Cash-burning (FCF negative)No competitive moatWeak Piotroski F-Score: 2/9Quality concerns

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Volume
0.0
Obv
1.0
Ma Position
4.0
Rsi
5.5
Volume distribution (falling OBV)Above 200-day MA
GatesMomentum 2.1<4.5EARNINGS PROXIMITY 7d<=7dA.R:R 2.6 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Aggressive
RSI
46 · Neutral
↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $33.30Resistance $40.51

Price Targets

$32
$45
A.Upside+30.1%
A.R:R2.6:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (1.4 < 4.0)
! Momentum score 2.1/10 — below 4.5 minimum
! EARNINGS_PROXIMITY:7d<=7d

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-05-07 (7d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is TYRA stock a buy right now?

Sell if holding. Engine safety override at $34.26: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 2.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $32.30. Score 4.9/10, moderate confidence.

What is the TYRA stock price target?

Take-profit target: $44.58 (+30.2% upside). Prior stop was $32.30. Stop-loss: $32.30.

What are the risks of investing in TYRA?

Quality below floor (1.4 < 4.0).

Is TYRA overvalued or undervalued?

Tyra Biosciences, Inc. trades at a P/E of N/A (forward -13.2). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about TYRA?

18 analysts cover TYRA with a consensus score of 4.4/5. Average price target: $51.

What does Tyra Biosciences, Inc. do?Tyra Biosciences is a clinical-stage precision oncology company developing oral FGFR inhibitors using its proprietary...

Tyra Biosciences is a clinical-stage precision oncology company developing oral FGFR inhibitors using its proprietary SNAP platform for targeted oncology and genetically defined conditions. Its lead program, oral dabogratinib (FGFR3-selective), is in three Phase 2 trials for urothelial cancers (LG-UTUC, IR NMIBC) and achondroplasia in children; accumulated deficit was $371.3 million as of December 31, 2025.

Related stocks: INCY (Incyte Corporation) · NVAX (Novavax, Inc.) · CPRX (Catalyst Pharmaceuticals, Inc.) · AUPH (Aurinia Pharmaceuticals Inc) · INVA (Innoviva, Inc.)